Nanoparticles for local delivery of siRNA in lung therapy

Adv Drug Deliv Rev. 2021 Dec:179:114038. doi: 10.1016/j.addr.2021.114038. Epub 2021 Nov 3.

Abstract

An overview of the application of natural and synthetic, non-viral vectors for oligonucleotide delivery into the lung is presented in this review, with a special focus on lung cancer. Due to the specificity of the respiratory tract, its structure and natural barriers, the administration of drugs (especially those based on nucleic acids) is a particular challenge. Among widely tested non-viral drug and oligonucleotides carriers, synthetic polymers seem to be most promising. Unique properties of these nanoparticles allow for essentially unlimited possibilities regarding their design and modification. This gives hope that optimal nanoparticles with ideal nucleic acid carrier properties for lung cancer therapy will eventually emanate.

Keywords: Drug delivery; Lung cancer therapy; Nanoparticles; Nucleic acids administration.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Inhalation
  • Asthma / drug therapy
  • Drug Carriers / chemistry
  • Humans
  • Lung / physiology*
  • Lung Neoplasms / drug therapy
  • Macrophages, Alveolar / metabolism
  • Mucus / metabolism
  • Polymers / chemistry
  • Pulmonary Surfactants / metabolism
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / therapeutic use

Substances

  • Drug Carriers
  • Polymers
  • Pulmonary Surfactants
  • RNA, Small Interfering